Wilson Sonsini Counsels SpyGlass Pharma on Purchase of Advanced Vision Science

On October 1, 2026, SpyGlass Pharma, dedicated to treating chronic eye conditions, announced the acquisition of Advanced Vision Science (AVS) for approximately $13 million in cash. This acquisition enhances SpyGlass Pharma’s manufacturing capabilities for its Phase 3 lead product, the BIM-IOL System, and allows for the integration of premium lenses into its drug delivery system. The legal team from Wilson Sonsini Goodrich & Rosati advised on this transaction.

Key Individuals Involved:

Corporate

• Dan Koeppen
• Robert Wernli
• Bridget Balisy

Mergers and Acquisitions

• Catherine Riley Tzipori
• Jason Breen
• Orlando Hodges

Technology Transactions

• Lowell Segal
• Shefali Lumb
• Gopika Das Mesrobian

Tax

• Myra Sutanto Shen

Employee Benefits and Compensation

• Matthew Norgard

Real Estate

• Susan Reinstra
• Paige Baker

Regulatory

• Eva Yin

For more details, refer to SpyGlass Pharma’s news release.